Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

As I was getting up from my visit with Mrs. Gregory, her right hand went to the base of her neck. Dr. Smith, do you think this little lump is anything?” Though doing her best to portray calm, she ...

Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

Omitting sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer undergoing breast-conserving surgery may not increase the risk for recurrence over 5 years, according to findings ...

The 3-year axillary RFS rate was 99.2% with axillary lymph node dissection and 98.8% with less-invasive procedures. Less-invasive lymph node procedures are noninferior to axillary lymph node ...

To investigate this further, first author, Gabriella N. Tortorello, MD, and a research team from the University of Pennsylvania, performed a retrospective cohort study with data from the National ...

Please provide your email address to receive an email when new articles are posted on . Armando E. Giuliano, MD, will receive the 2025 William L. McGuire Memorial Lecture Award. Giuliano is being ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

In almost all solid tumors - i.e. cancers with a solid tissue structure - the detection of tumor cells in the lymph nodes is considered a decisive marker for the progression of the disease. Lymph node ...